Daiichi Sankyo Company, Limited (Japanese: 第一三共株式会社, Hepburn: Daiichi Sankyō Kabushiki-gaisha) is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022.[3] The company owns the American pharmaceutical company American Regent.
Daiichi Sankyo, Inc. (DSI) began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development (Daiichi Sankyo Pharma Development), is headquartered in Basking Ridge, New Jersey.
Daiichi Sankyo Europe, GmbH (DSE), the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.
Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
^"Our Leadership - Our Mission & Strengths - About Us". Daiichi Sankyo. Retrieved 13 April 2023.
^"Corporate Management Information". Daiichi Sankyo US. Retrieved 13 April 2023.
^ ab"Consolidated Financial Results for Year Ended March 31, 2023 (Fiscal 2022)" (PDF). Daiichi Sankyo. 27 April 2023. Retrieved 18 May 2023.
^"About Us". Daiichi Sankyo. Retrieved 15 May 2023.
^"Value Report 2020" (PDF). Daiichi Sankyo Group. 31 March 2020. p. 45. Retrieved 30 November 2020.
DaiichiSankyo Company, Limited (Japanese: 第一三共株式会社, Hepburn: DaiichiSankyō Kabushiki-gaisha) is a global pharmaceutical company and the second-largest...
the course of its history. In 2008, Japanese pharmaceutical company DaiichiSankyo acquired a controlling share in Ranbaxy and in 2014, Sun Pharma acquired...
Sankyo (三共, Sankyō) means "third one" in Japanese. It may refer to: DaiichiSankyo Co. (第一三共, DaiichiSankyō), a Japanese pharmaceutical company and a...
agreement with DaiichiSankyo to distribute Nexium in Japan. In September 2011, Nexium was approved for sale and was launched by DaiichiSankyo in Japan. Esomeprazole...
was sold to Japanese drugmaker DaiichiSankyo. Singh resigned in 2009 after Ranbaxy posted losses and after DaiichiSankyo decided to get more actively...
developmental code name DS-5565) is a gabapentinoid medication developed by DaiichiSankyo. Gabapentin and pregabalin are also members of this class. As a gabapentinoid...
identified by DaiichiSankyo Co., which brought ofloxacin and levofloxacin to the market. Sitafloxacin is currently marketed in Japan by DaiichiSankyo under...
the company announced it would co-commercialise naloxegol along with DaiichiSankyo in a deal worth up to US$825 million. Towards the end of April the company...
pharmaceutical company DaiichiSankyo for $805 million and an additional $130 million in potential milestone payments. DaiichiSankyo announced the shutdown...
Azelnidipine is L and T calcium channel blocker. It is sold in Japan by Daiichi-Sankyo pharmaceuticals, Inc. Unlike nicardipine, it has a gradual onset and...
2002. Olmesartan and Sevikar HCT combined is marketed worldwide by DaiichiSankyo, in India by Abbott Healthcare Pvt. Ltd. under the trade name WinBP...
Shanghvi became managing director. In April 2014 Sun, Ranbaxy, and DaiichiSankyo (the majority shareholder in Ranbaxy) agreed that Sun would acquire...
is currently marketed under the name Inavir by DaiichiSankyo. Biota Pharmaceuticals and DaiichiSankyo co-own Laninamivir. On 1 April 2011, BARDA awarded...
MK-1022) is an experimental antibody–drug conjugate developed by Merck and DaiichiSankyo to treat non-small-cell lung cancer. Yu, H.A.; Baik, C.S.; Gold, K.;...
ONE™ platform. Later that month, Inovalon announced a partnership with DaiichiSankyo, Inc. to help develop outcomes-based contracts addressing opioid pain...
the NASDAQ exchange under the symbol "AMBI". Ambit was acquired by DaiichiSankyo in 2014 and is no longer traded on the NASDAQ exchange. As of March 2014[update]...
Compared with warfarin it has fewer drug interactions. It was developed by DaiichiSankyo and approved in July 2011, in Japan for prevention of venous thromboembolisms...
release: DaiichiSankyo Initiates Phase 3 study of CS-3150, a Novel Mineralocorticoid Receptor Antagonist for Treatment of Essential Hypertension". Daiichi Sankyo...
such as Eldew and Amihop. It also manufactures for companies such as DaiichiSankyo Healthcare Co., Ltd. to develop products like the moisturizing detergent...
antimineralocorticoid which was discovered by Exelixis and developed by DaiichiSankyo Company and is approved in Japan for the treatment of hypertension....
and launched in September 2012 by both Mitsubishi Tanabe Pharma and DaiichiSankyo in Japan. It is approved for use in Japan, Argentina, Korea and India...
Global Information
$ 9.44 billion USD (FY 2022) (¥ 1,278 billion JPY) (FY 2022)